Skip to content
Parakho

Venus Remedies Ltd

NSE VENUSREMBSE 526953

Q1 FY27, unaudited

Revenue
₹178.86 Cr
Profit after tax
₹22.97 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations178.86+35.60%769.60
Other income2.62−69.85%12.58
Total income181.48+29.08%782.18
Employee benefit expense23.37+15.12%88.68
Finance costs0.00−100.00%0.04
Depreciation & amortisation6.77+9.55%25.67
Total expenses151.44+18.33%648.03
Profit before tax30.04+138.22%134.15
Tax expense7.07+134.88%31.37
Profit after tax22.97+139.27%102.78
Total comprehensive income28.88+141.47%102.79
Earnings per share
Earnings per share, basic₹17.18₹76.89
Earnings per share, diluted₹17.18₹76.89

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Venus Remedies Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 45 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.